Company Overview
Snapshot
Founded in January 2003 by Roni Kramer, Kamedis operates with 11–50 employees. The company focuses on developing botanical skin care products. In January 2019, Kamedis received a Notice of Allowance for its first US patent on botanical eczema treatment, marking a significant intellectual property milestone.
Business overview
Kamedis develops and markets dermatologist-tested botanical skin care products designed to address various chronic skin conditions, including eczema, acne, dandruff, psoriasis, dry skin, and itchy/irritated skin. The company's products are formulated using botanical extracts produced in a certified manufacturing facility, ensuring quality and potency. Kamedis serves the health and life sciences sector, specifically targeting the dermatology and cosmetics markets, with products available in the United States, China, Taiwan, the Philippines, Singapore, and several European countries.
Strategic signal
In January 2019, Kamedis secured a Notice of Allowance for its first US patent related to botanical eczema treatment. This intellectual property validation is a strong signal to investors, demonstrating the company's commitment to scientific rigor and its ability to protect its innovative botanical formulations in a key market. This patent enhances Kamedis's competitive position and potential for market expansion in the dermatological care segment.
Log in to access full profile ›Company Intelligence Q&A
- What is Kamedis's primary focus?
- Kamedis specializes in developing effective, dermatologist-tested botanical skin care products for chronic skin conditions such as eczema, acne, dandruff, psoriasis, dry skin, and itchy/irritated skin.
- When was Kamedis founded and by whom?
- Kamedis was founded in January 2003 by Roni Kramer.
- In which countries are Kamedis products sold?
- Kamedis products are sold in the United States, China, Taiwan, the Philippines, Singapore, and several European countries.
- What was a significant intellectual property milestone for Kamedis?
- In January 2019, Kamedis received a Notice of Allowance for its first US patent on botanical eczema treatment.
- What kind of research supports Kamedis's products?
- Kamedis's products are based on extensive scientific research and development, including studies on hundreds of traditional Chinese medicine botanicals and their combinations, with final products validated by dermatologists and backed by clinical trials.